EP4031110
Skammtaform fyrir TYK2-hindra
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
18.9.2020EP published:
24.12.2025EP application number:
20781719.8
EP translation filed:
30.1.2026Grant published:
11.2.2026EPO information:
European Patent Register
Max expiry date:
17.9.2040Expiry date:
17.9.2026
Title in English:
DOSAGE FORMS FOR TYK2 INHIBITORSLanguage of the patent:
English
Timeline
Today
18.9.2020EP application
24.12.2025EP Publication
30.1.2026Translation submitted
11.2.2026Registration published
17.9.2026Expires
Owner
Name:
Bristol-Myers Squibb CompanyAddress:
Route 206 and Province Line Road, Princeton, NJ 08543, US
Inventor
Name:
BADAWY, Sherif Ibrahim FaragAddress:
Princeton, New Jersey 08543, US
Name:
BROWN, Jonathan R.Address:
Moreton Merseyside CH46 1QW, GB
Name:
CHOI, Candice Y.Address:
Princeton, New Jersey 08543, US
Name:
GESENBERG, ChristophAddress:
Princeton, New Jersey 08543, US
Name:
GRAY, VivienneAddress:
Moreton Merseyside CH46 1QW, GB
Name:
JONES, John WynneAddress:
Moreton Merseyside CH46 1QW, GB
Name:
KESTUR, UmeshAddress:
Princeton, New Jersey 08543, US
Name:
VIG, Balvinder S.Address:
Devens, Massachusetts 01434, US
Name:
YIN, Xiaotian, S.Address:
Princeton, New Jersey 08543, US
Name:
ZORDAN, Christopher A.Address:
Princeton, New Jersey 08543, US
Name:
BLOOM, CoreyAddress:
Bend, Oregon 97702, US
Name:
YATES, IanAddress:
Bend, Oregon 97701, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201962902218 PDate:
18.9.2019Country:
US
Classification
Categories:
A61K 9/00, A61K 9/14, A61K 9/16, A61K 31/00, A61K 47/02, A61K 47/12, A61K 47/26, A61K 47/38, A61K 31/501, A61P 29/00, A61P 37/06